B · Normal
[AstraZeneca: Datroway approved in China for metastatic triple-negative breast cancer not suitable for PD-1/PD-L1 inhibitor treatment] On October 8, AstraZeneca China announced that Datroway® (English trade name: Datroway) was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. ®, generic name: dabrotuzumab for injection) was officially approved by the China National Medical Products Administration (NMPA) on September 29, 2026, for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor treatment.
medicine 🕐 2026-10-08 16:49
#medicine #Pharmaceutical business #European stock trends
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

On October 9, the Stoxx Europe 600 Telecommunications Index expanded its decline 10-09 16:11 [European stocks collectively opened higher] On October 9, the European Stoxx in 10-09 15:02 On October 9, India plans to introduce stricter control measures on prescription 10-09 13:44 [Dongguang Pharmaceutical's double insulin degluaspart was approved and became t 10-08 16:46 On October 8, the European Stoxx 600 Index fell to a nearly four-month low, with 10-08 15:27 [European stocks collectively opened lower] On October 8, the European Stoxx 50 10-08 15:02

Comments

0/500
Captcha (click to refresh)
No comments yet